Diana Brainard
Director Ejecutivo en ALLOVIR, INC. .
Fortuna: 669 395 $ al 30/04/2024
Cargos activos de Diana Brainard
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ALLOVIR, INC. | Director/Miembro de la Junta | 01/07/2020 | - |
| Director Ejecutivo | 17/05/2021 | - | |
| Independent Dir/Board Member | 01/04/2019 | - | |
| NEKTAR THERAPEUTICS | Director/Miembro de la Junta | 11/11/2021 | - |
| Independent Dir/Board Member | 11/11/2021 | - | |
Affinia Therapeutics, Inc.
 Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Director/Miembro de la Junta | 08/03/2022 | - |
| Independent Dir/Board Member | 08/03/2022 | - | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Inversor de Capital Privado | - | - |
Historial de carrera de Diana Brainard
Antiguos cargos conocidos de Diana Brainard.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/01/2015 | 01/01/2021 |
Formación de Diana Brainard.
| Brown University | Undergraduate Degree |
| Tulane University School of Medicine | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 8 |
Operativa
| Director/Board Member | 3 |
| Independent Dir/Board Member | 3 |
| Undergraduate Degree | 1 |
Sectorial
| Health Technology | 5 |
| Consumer Services | 3 |
| Finance | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| ALLOVIR, INC. | Health Technology |
| NEKTAR THERAPEUTICS | Health Technology |
| Empresas privadas | 2 |
|---|---|
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Health Technology |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
- Bolsa de valores
- Insiders
- Diana Brainard
- Experiencia